Receptor News and Research

RSS

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.

9 Dec 2014

Researchers develop nanomimics of host cell membranes that trick malaria parasites

Malaria parasites invade human red blood cells, they then disrupt them and infect others. Researchers at the University of Basel and the Swiss Tropical and Public Health Institute have now developed so-called nanomimics of host cell membranes that trick the parasites. This could lead to novel treatment and vaccination strategies in the fight against malaria and other infectious diseases.

9 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report.

8 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.

7 Dec 2014

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

BRI signs license agreement with SOBI for Kineret (anakinra)

Baylor Research Institute, the research arm of the Baylor Scott & White Health, announced that it has signed an agreement with Swedish Orphan Biovitrum AB (Sobi) to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis (SJIA or SOJIA) using interleukin-1 (IL-1) beta antagonists.

6 Dec 2014

Hormone leptin increases blood pressure that occurs with weight gain

Leptin, a hormone that regulates the amount of fat stored in the body, also drives the increase in blood pressure that occurs with weight gain, according to researchers from Monash University and the University of Cambridge.

5 Dec 2014

Researchers discover link between obesity and hypertension

The link between obesity and cardiovascular diseases is well acknowledged. Being obese or overweight is a major risk factor for the development of elevated blood pressure, and cardiovascular diseases. But it has net been known how obesity increases the risk of high blood pressure, making it difficult to develop evidence based therapies for obesity, hypertension and heart disease.

5 Dec 2014

New drug offers hope for victims of spinal cord injury

Scientist in the U.S have developed a drug that could help paralysed victims of spinal cord injury regain their ability to move.

4 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

New chemical compound shows promise in restoring function lost to spinal cord injury

Case Western Reserve scientists have developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury. The compound, which the researchers dubbed intracellular sigma peptide (ISP), allowed paralyzed muscles to activate in more than 80 percent of the animals tested.

4 Dec 2014

UAB research suggests potential therapeutic target for patients with frontotemporal dementia

Drugs that boost the function of a specific type of neurotransmitter receptor may provide benefit to patients with the second most common type of dementia, according to research by scientists at the University of Alabama at Birmingham published today in the Journal of Neuroscience.

4 Dec 2014

SAFit-ligands provide foundation for novel treatment of stress-related psychiatric disorders

The FK506-binding protein 51 (FKBP51) is an established risk factor for stress-related psychiatric disorders such as major depression. Drug discovery for FKBP51 has been hampered by the inability to pharmacologically differentiate against the very similar functional counterplayer FKBP52.

3 Dec 2014

Researchers identify possible prognostic biomarker in triple-negative breast cancer

"Triple-negative" breast cancer (TNBC) occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER-/PR-/HER2-).

2 Dec 2014

Physiologists use new method to identify two odorant receptors in live mice

A group of physiologists led by University of Kentucky's Tim McClintock have identified the receptors activated by two odors using a new method that tracks responses to smells in live mice.

2 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Receptor News and Research

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Researchers develop nanomimics of host cell membranes that trick malaria parasites

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Researchers identify new targets for future CLL therapies

Study: Key protein may help prevent tumor growth, promote wound healing

Innovative cell therapy shows highly promising results in pediatric patients with ALL

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

BRI signs license agreement with SOBI for Kineret (anakinra)

Hormone leptin increases blood pressure that occurs with weight gain

Researchers discover link between obesity and hypertension

New drug offers hope for victims of spinal cord injury

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

New chemical compound shows promise in restoring function lost to spinal cord injury

UAB research suggests potential therapeutic target for patients with frontotemporal dementia

SAFit-ligands provide foundation for novel treatment of stress-related psychiatric disorders

Researchers identify possible prognostic biomarker in triple-negative breast cancer

Physiologists use new method to identify two odorant receptors in live mice

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News